Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study.

摘要: BACKGROUND Individuals with advanced gastric cancer (AGC) who present severe peritoneal metastasis (SPM) have poor prognosis. This study aimed to evaluate efficacy and safety of second-line treatment for patients such condition. METHODS retrospective included receiving taxane-based chemotherapy at three Japanese institutions between 2010 2016. Patients AGC SPM were if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support. RESULTS In this study, 43 (40%) 108 an Eastern Cooperative Oncology Group Performance Status score ≥ 2, the median serum albumin level was 3.3 g/dL. Ramucirumab used in combination paclitaxel 21 patients. The overall survival (OS) progression-free (PFS) 5.1 2.8 months, respectively. Inadequate considered a negative prognostic factor both OS PFS multivariate analysis. Three treatment-related deaths observed, which include those attributed febrile neutropenia, gastrointestinal perforation, pneumonitis. Common grade ≥ 3 adverse events neutropenia (35%), leukopenia (30%), anemia (24%), anorexia (16%). We observed 8% perforation 4% patients, conditions dominantly intake. CONCLUSION Taxane-based effective safe SPM. Attention must be provided when treating as are likely short prognosis serious toxicities.